Skip to main content

Zoetis Inc. Pain and sedation revenue

  • ZTS · NYSE
  • Pharmaceuticals
  • S&P 500
$83.82+1.04%Close 13 Nov 2026

Pain and sedation revenue at Zoetis Inc. came to $200.0M for the quarter to 30 Sep 2026, unchanged from a year earlier.

As Zoetis Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 5 Nov 2026.

By quarter

$194.0MDec 2023$194.0MMar 2024$221.0MJun 2024$219.0MSep 2024$217.0MDec 2024$207.0MMar 2025$223.0MJun 2025$200.0MSep 2025$210.0MDec 2025$203.0MMar 2026$217.0MJun 2026$200.0MSep 2026
Zoetis Inc. Pain and sedation revenue, every reported period
Period endingPain and sedation revenueChange on a yearFiled
30 Sep 2026$200.0Munchanged5 Nov 2026
30 Jun 2026$217.0Mdown 2.7%6 Aug 2026
31 Mar 2026$203.0Mdown 1.9%7 May 2026
31 Dec 2025$210.0Mdown 3.2%12 Feb 2026
30 Sep 2025$200.0Mdown 8.7%4 Nov 2025
30 Jun 2025$223.0Mup 0.9%5 Aug 2025
31 Mar 2025$207.0Mup 6.7%6 May 2025
31 Dec 2024$217.0Mup 11.9%13 Feb 2025
30 Sep 2024$219.0Mup 49.0%4 Nov 2024
30 Jun 2024$221.0Mup 52.4%6 Aug 2024
31 Mar 2024$194.0Mup 67.2%2 May 2024
31 Dec 2023$194.0M—13 Feb 2024
30 Sep 2023$147.0M—2 Nov 2023
30 Jun 2023$145.0M—8 Aug 2023
31 Mar 2023$116.0M—4 May 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Zoetis Inc.: Dogs and Cats revenue · Livestock revenue · Parasiticides revenue · Vaccines revenue · Cattle revenue · Dermatology revenue · Anti-infectives revenue · Animal health diagnostics revenue · Swine revenue · Poultry revenue · Fish revenue · Horses revenue · Sheep and other revenue · Contract manufacturing & human health revenue · Medicated feed additives revenue · Companion Animal revenue · U.S. revenue · International revenue · financial statements

Every KPI and segment of ZTS, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.